NCT06799598

Brief Summary

In vitro fertilization (IVF) has revolutionized assisted reproductive techniques, bringing hope to thousands of people seeking to fulfill their dream of parenthood. However, patients with low ovarian reserve face additional challenges, such as limited response to ovarian stimulation and difficulty in obtaining good-quality eggs. Innovative protocols such as Duostim (dual stimulation) have shown promise in these cases, allowing the maximum number of eggs to be retrieved in a short period of time. In addition, technological advances in the analysis of the quality of mature eggs, such as the use of the Magenta tool, are transforming the way specialists evaluate and select the best gametes to increase the chances of success. This article explores how these approaches complement each other, offering new possibilities for patients with low ovarian reserve and raising the standards of reproductive medicine.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
92

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2025

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

January 23, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 29, 2025

Completed
Last Updated

January 29, 2025

Status Verified

January 1, 2025

Enrollment Period

9 months

First QC Date

January 23, 2025

Last Update Submit

January 23, 2025

Conditions

Infertility

Outcome Measures

Primary Outcomes (1)

  • Follicular and luteal phase oocytes Magenta score

    Assessment of oocyte potential to generate blastocysts at two different times of oocyte retrieval

    30 days

Study Arms (2)

DuoStim1

Follicular phase Stimulation

DuoStim2

Luteal Phase stimulation

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women of reproductive age undergoing ovarian stimulation for in vitro fertilization (IVF)

You may qualify if:

  • Patients undergoing IVF with DUOSTIM protocol and Magenta analysis of mature eggs.

You may not qualify if:

  • Canceled Duostim Magenta IVF cycles

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vida - Medicina Reprodutiva

Rio de Janeiro, Rio de Janeiro, 22793-080, Brazil

Location

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
30 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D.

Study Record Dates

First Submitted

January 23, 2025

First Posted

January 29, 2025

Study Start

May 1, 2024

Primary Completion

January 15, 2025

Study Completion

January 15, 2025

Last Updated

January 29, 2025

Record last verified: 2025-01

Locations

BR(1)